Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 136 participants.

Also called NCT03323476

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 136 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03323476
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03323476. Randomized; no masking; primary purpose treatment. Start 2018-02-02 (actual); primary completion 2028-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
Acronym
MASTER-ANCA
Condition
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Condition
End Stage Renal Disease
Intervention (Other)
Discontinuation (or not initiation) of Immunosuppressive Therapy
Intervention (Drug)
Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Lead sponsor
Centre Hospitalier Departemental Vendee (class: other)

Record details

Record id
cardio:ct-nct03323476
Content hash
af9deb92626d29a21ead4744549c28263c97d7199c6156fb4c7da52e3edddc47